|
業務類別
|
Diagnostics & Research |
|
業務概覽
|
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product,clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment. |
| 公司地址
| 1165 Eastlake Avenue East, Seattle, WA, USA, 98109 |
| 電話號碼
| +1 206 659-0067 |
| 傳真號碼
| +1 206 659-0667 |
| 公司網頁
| https://www.adaptivebiotech.com |
| 員工數量
| 624 |
| Mr. Chad M. Robins |
Chairman of the Board and Chief Executive Officer |
美元 698.26K |
24/04/2026 |
| Ms. Julie Rubinstein |
President and Chief Operating Officer |
美元 542.38K |
24/04/2026 |
| Dr. Harlan Robins, PhD |
Chief Scientific Officer |
美元 558.65K |
24/04/2026 |
| Mr. Francis Lo |
Chief People Officer |
-- |
24/04/2026 |
| Dr. Sharon Benzeno, PhD |
Chief Commercial Officer, Immune Medicine |
-- |
24/04/2026 |
| Mr. Kyle Piskel |
Chief Financial Officer and Principal Accounting Officer |
美元 399.95K |
24/04/2026 |
| Ms. Susan Bobulsky |
Chief Commercial Officer, Minimal Residual Disease |
美元 435.75K |
24/04/2026 |
|
|
| Mr. Peter M. Neupert |
Lead Independent Director |
24/04/2026 |
| Dr. Robert M. Hershberg, M.D.,PhD |
Independent Director |
24/04/2026 |
| Ms. Michelle Griffin |
Independent Director |
24/04/2026 |
| Mr. Chad M. Robins |
Chairman of the Board and Chief Executive Officer |
24/04/2026 |
| Ms. Katey Einterz Owen |
Independent Director |
24/04/2026 |
|
|
|
|
